Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
Go back to Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1176.10 -13.31 (1.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1189.41 | 52 Week High | $88.16 | |||
| Open | $1182.25 | 52 Week Low | $67.88 | |||
| Day High | $1190.11 | P/E | 272.25 | |||
| Day Low | $1171.71 | EPS | $4.32 | |||
| Volume | 2,647,145 | |||||
